Abstract
Background: Hybrid polymeric materials have been in research focus owing to their outstanding progression in drug targeting. A new Quality by Design approach by RP-HPLC was developed and validated for the estimation of hybrid polymeric nanoparticles of Ritonavir in rat plasma.
Objective: The main objective of the present study was to develop and validate a simple, robust, and accurate method by QbD approach for the detection of hybrid polymeric nanoparticles of Ritonavir (RTV) in plasma.
Methods: The mobile phase consisting of a mixture of Acetonitrile: HPLC grade water (60:40 v/v), 1.0 ml/min flow rate and UV detection at 240 nm. Critical Analytical Attributes (CAAs) were screened and selected by Taguchi orthogonal array model. Box-Behnken's three-level, the 3- factorial design, was employed to create and analyze a "Design Space" (DoE). This design was statistically analyzed by ANOVA, contour-plot, and 3D response surfaces plots, which demonstrated that the model was statistically significant. The developed method was validated as per the ICH guidelines Q2 (R1).
Results: The developed method showed excellent linearity between 100 and 600 ng/mL with good regression (R2>0.998), LOD (10 ng/mL) and LOQ (30 ng/mL). The validation results of the tested parameters were found within the acceptable limit.
Conclusion: From the study, it was concluded that QbD driven bioanalytical method is suitable for the in-vitro and in-vivo estimation of RTV from bulk as well as from hybrid polymeric nanoparticles formulation.
Keywords: Design of Experiments (DoE), hybrid polymeric nanoparticles, ICH Guidelines, RP-HPLC method, Ritonavir, rat plasma.
Graphical Abstract
[http://dx.doi.org/10.2174/1573412915666190206124808]
[http://dx.doi.org/10.5414/CPP39400] [PMID: 11563687]
[http://dx.doi.org/10.1186/s13065-016-0232-6] [PMID: 28101128]
[http://dx.doi.org/10.1016/j.jpba.2008.08.007] [PMID: 18801634]
[http://dx.doi.org/10.1128/AAC.02748-13] [PMID: 24566184]
[http://dx.doi.org/10.1155/2009/709478]
[http://dx.doi.org/10.1155/2008/539849]
[http://dx.doi.org/10.31638/IJPRS.V1.I1.00017]
[http://dx.doi.org/10.1016/j.chroma.2005.07.031] [PMID: 16395807]
[http://dx.doi.org/10.1002/elps.200390078] [PMID: 12601735]
[http://dx.doi.org/10.5530/phm.2017.8.23]
[http://dx.doi.org/10.1016/j.ijpharm.2020.119794] [PMID: 32828978]
[http://dx.doi.org/10.1111/jphp.12737] [PMID: 28471000]
[http://dx.doi.org/10.1208/s12249-021-02068-w] [PMID: 34184163]
[http://dx.doi.org/10.1155/2015/868727] [PMID: 25722723]
[http://dx.doi.org/10.1002/jps.22325] [PMID: 21280050]
[http://dx.doi.org/10.1016/j.jpba.2015.08.042] [PMID: 26378979]
[http://dx.doi.org/10.2174/1573412915666181113130245]
[http://dx.doi.org/10.2174/1573412914666180523092012]
[http://dx.doi.org/10.1016/j.jscs.2012.12.001]
[http://dx.doi.org/10.3797/scipharm.1107-24] [PMID: 22145109]
[http://dx.doi.org/10.1016/j.aca.2009.08.010] [PMID: 19733744]
[http://dx.doi.org/10.1365/s10337-010-1550-9]
[http://dx.doi.org/10.1016/j.ijpharm.2014.05.024] [PMID: 24853459]
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2018024751] [PMID: 30317969]
[http://dx.doi.org/10.1016/j.jsps.2015.03.004] [PMID: 26903773]
[http://dx.doi.org/10.5772/intechopen.69501]
[http://dx.doi.org/10.1021/acs.oprd.9b00238]
[http://dx.doi.org/10.1002/bmc.4169] [PMID: 29244215]
[http://dx.doi.org/10.1016/j.jchromb.2020.122300] [PMID: 32771967]
[http://dx.doi.org/10.4097/kja.d.18.00242] [PMID: 30157585]
[http://dx.doi.org/10.1016/j.jsps.2015.02.001] [PMID: 26594122]
[http://dx.doi.org/10.1080/10826076.2013.840841]